21.1116.02001

Sixty-seventh Legislative Assembly of North Dakota

HOUSE BILL NO. 1514

Introduced by

Representatives Tveit, Fisher, Kasper, K. Koppelman, Paulson
Senators Clemens, O. Larsen, Luick
(Approved by the Delayed Bills Committee)

- 1 A BILL for an Act to create and enact a new section to chapter 23-16, a new section to chapter
- 2 43-15, and a new section to chapter 43-17 of the North Dakota Century Code, relating to a
- 3 hospital patient's right to try-off-label use drugs, a hospital ban on discrimination based on
- 4 <u>vaccinevaccination</u> status, pharmacist fulfillment of off-label drug use prescriptions for the
- 5 treatment of COVID-19, and the board of medicine's authority to bring disciplinary actions; and
- 6 to provide an effective date.

7 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:

- 8 **SECTION 1.** A new section to chapter 23-16 of the North Dakota Century Code is created 9 and enacted as follows:
- 10 Right to try off-label use drugs Ban on discrimination based on vaccine vaccination
 11 status.
- 12 <u>1. If a patient is prescribed a United States food and drug administration-approved drug</u>
 13 <u>for off-label use, a hospital shall honor that prescription.</u>
- SECTION 2. A new section to chapter 43-15 of the North Dakota Century Code is created and enacted as follows:
- 18 Off-label use COVID-19.
- 19 If a pharmacist receives a United States food and drug administration-approved drug
 20 prescription for the off-label treatment or prevention of a disease or medical conditionsevere
 21 acute respiratory syndrome coronavirus 2 identified as SARS-CoV-2, or any mutation or viral
 22 fragments of SARS-CoV-2, the pharmacist may not refuse to dispense the drug based on the
 23 pharmacist's professional judgment regarding the appropriateness of the prescription. This

- 1 section does not prevent the pharmacist from contacting the prescriber regarding the 2 prescription. 3 SECTION 3. A new section to chapter 43-17 of the North Dakota Century Code is created 4 and enacted as follows: 5 COVID-19 - Limitations on disciplinary actions. 6 The board may not take disciplinary action against a licensee based on the licensee 7 distributing documented medical information, providing information regarding the licensee's 8 professional experience or observations, or speaking against a public official. The board may 9 not bring a disciplinary action against a licensee based on the prescription of a United States 10 food and drug administration-approved drug for the off-label treatment or prevention of severe 11 acute respiratory syndrome coronavirus 2 identified as SARS-CoV-2, or any mutation or viral 12 fragments of SARS-CoV-2.
- SECTION 4. EFFECTIVE DATE. This Act becomes effective upon its filing with the secretary of state.